tbuckley/cabot-search huggingface dataset:
Prospective Evaluation of Anthracycline-Related Early Cardiac Damage: How Do We Monitor It?
Authors: Renato Ciotti, Giovanni Ucci, Giuseppina Belotti, Edoardo Facchi, Marco Cremonesi, Cinzia Gatti, Giovanni Baccheta
Journal: Journal of Clinical Oncology (2001)

Article Tools SPECIAL DEPARTMENTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2001.19.22.4269 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 11709572 Prospective Evaluation of Anthracycline-Related Early Cardiac Damage: How Do We Monitor It? Renato CiottixRenato CiottiSearch for articles by this author , Giovanni UccixGiovanni UcciSearch for articles by this author , Giuseppina BelottixGiuseppina BelottiSearch for articles by this author , Edoardo FacchixEdoardo FacchiSearch for articles by this author , Marco CremonesixMarco CremonesiSearch for articles by this author , Cinzia GattixCinzia GattiSearch for articles by this author , Giovanni BacchetaxGiovanni BacchetaSearch for articles by this author Show More Ospedale A. Manzoni, Azienda Ospedaliera Lecco, Lecco, ItalyOspedali Riuniti di Treviglio, Aziena Ospedaliera de Treviglio Bergamo, Bergamo, Italy https://doi.org/10.1200/JCO.2001.19.22.4269 First Page Full Text PDF Figures and Tables © 2001 by American Society of Clinical Oncology
ACF chromatin-remodeling complex mediates stress-induced depressive-like behavior
Authors: HaoSheng Sun, Diane M Damez-Werno, Kimberly N Scobie, Ning-Yi Shao, Caroline Dias, Jacqui Rabkin, Ja Wook Koo, Erica Korb, Rosemary C Bagot, Francisca H Ahn, Michael E Cahill, Benoit Labonté, Ezekiell Mouzon, Elizabeth A Heller, Hannah Cates, Sam A Golden, Kelly Gleason, Scott J Russo, Simon Andrews, Rachael Neve, Pamela J Kennedy, Ian Maze, David M Dietz, C David Allis, Gustavo Turecki, Patrick Varga-Weisz, Carol Tamminga, Li Shen, Eric J Nestler
Journal: Nature Medicine (2015)
Prognostic Impact of Clinician-Based Interpretation of FDG-PET/CT Reports Obtained in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma.
Authors: Karen Juul Mylam, Tarec Christoffer El-Galaly, Peter de Nully Brown, Bodil Himmelstrup, Dorte Gillstrøm, Ida Blok Sillesen, Lars Munksgaard, Bjarne Bach Pedersen, Ilse Christiansen, Paw Jensen, Anne Lerberg Nielsen, Lars Møller Pedersen
Journal: Blood (2012)
The natural history of gastric cancer and prognostic factors influencing survival.
Authors: A Y Bedikian, T T Chen, N Khankhanian, L K Heilbrun, C M McBride, M J McMurtrey, G P Bodey
Journal: Journal of Clinical Oncology (1984)

This study of 783 patients with histologically confirmed gastric carcinoma has confirmed the importance of several previously recognized patient- and tumor-related characteristics related to prognosis and identified some new ones. Of the tumor-related factors, the ones that showed the strongest relationship to survival following curative gastric resection were tumor stage, histologic type, breach of lymph-node capsule, sinus histiocytosis, and gross appearance. Of the tumor- and patient-related factors, the ones that showed the strongest relationship to survival from time of diagnosis of surgically noncurable disease were status of primary, liver metastasis, serum bilirubin level, ascites, extent of tumor burden, and weight loss. The effect of treatment with 5-fluorouracil (5-FU) on survival duration was at best only minimal. Only those patients who received two or more cycles of 5-FU therapy had survival advantage over the remaining patients. The use of regression analysis has made it possible to make predictions of the prognosis of the patients. These predictions could be used in future studies to determine comparability of prognosis of various groups included in different studies and different arms of a randomized study.
Prenatal exposure to PCBs and dioxins is associated with increased risk of wheeze and infectious diseases in 2-year old children
Authors: Solvor B. Stølevik, Unni C. Nygaard, Ellen Namork, Helen E. Kvalem, Helle M. Meltzer, Jan Alexander, Joost H. van Delft, Henk van Loveren, Martinus Løvik, Berit Granum
Journal: European Respiratory Journal (2011)

Food may contain toxicants (from environmental pollution or formed during food preparation). These toxicants may cross the placental barrier and affect the foetus' immune system. The aim of this study was investigated if prenatal exposure to acrylamide, dioxins and polychlorinated biphenyls (PCBs) affect the childrens immunological health status.

Pregnant women were recruited to the birth cohort BraMat (n=205). The occurrence of common childhood infections and periods of more than 10 days of dry cough, chest tightness or wheeze in the children was assessed by annual questionnaires ( n = 195 and 184, respectively). Maternal intake of toxicants was estimated from a validated food frequency questionnaire filled in by the mothers at midterm. The sum of six non-dioxin-like PCBs (PCB 28, 52, 101, 138, 153, 180), and the sum of toxic equivalents of 29 dioxins and dioxin-like PCBs were used. Logistic and linear multivariate regression analyses were performed. Adjustments were made for gender, mode of delivery, Apgar score, breast-feeding, parity, birth season and maternal history of atopy, age, BMI, education and smoking.

No associations between prenatal exposure to acrylamide and the health outcomes were found. At age one year, prenatal exposure to PCBs and dioxins was associated with increased risk of wheeze and exanthema subitum, and increased number of upper respiratory tract infections. Similar results were obtained in preliminary anaylsis for wheeze and upper resiratory track infections at two year of age.

Our findings suggests that prenatal exposure to dioxins and PCBs increase the risk of wheeze and infectious diseases during the first two years of life.
Emergency readmissions are highest in patients discharged at weekends
Authors: Zosia Kmietowicz
Journal: BMJ (2015)

The chances of needing emergency readmission to hospital are higher among patients who are discharged over the weekend than those sent home during the week, experimental figures have shown.

Data from 2014 collected by the Health and Social Care Information Centre (HSCIC)1 showed that the rate of emergency readmissions within seven days of discharge increased over the week, from a low of 3.6% on Mondays and Tuesdays to 4.8% on Saturdays and 5.8% on Sundays.

But wide variation occurred across trusts. The highest readmission rate after a …
Abstract 18402: Impact of Obesity on Outcomes After Percutaneous Coronary Intervention in Japanese Population: Obesity Paradox with High Waist Circumference but Not High BMI
Authors: Kenji Sakamoto, Seiji Hokimoto, Shuichi Oshima, Koichi Nakao, Kazuteru Fujimoto, Yuji Miyao, Hideki Shimomura, Ryusuke Tsunoda, Hideki Maruyama, Toyoki Hirose, Kenichi Tsujita, Yuichiro Arima, Tomonori Akasaka, Noriaki Tabata, Naohiro Komura, Kenshi Yamanaga, Takashi Miyazaki, Masanobu Ishii, Sunao Kojima, Koichi Kaikita, Sunao Nakamura, Hisao Ogawa
Journal: Circulation (2014)

Introduction: Although the counterintuitive association between obesity and mortality has been termed the obesity paradox, the evaluation of obesity was inconsistent, and evidence for an obesity paradox among past studies has been also less consistent. Hypothesis: This inconsistency may be due, in part, to a discrepancy between central obesity, estimated by waist circumference (WC), and body mass index (BMI) as patterns of adiposity. Methods: To elucidate the impact of obesity, 2817 subjects with both WC and BMI data were enrolled from the data of Kumamoto Intervention Conference Study (KICS), a multicenter registry, enrolling consecutive patients undergoing PCI in 15 centers from August 2008 to March 2011 in Japan. Subjects were stratified according to patterns of adiposity (WC or BMI), utilizing NCEP-ATPIII criteria and WHO classification. Results: Subjects’ mean age was 69.8 years, and 28% were female. There were 68 deaths during 12-month follow up. Although obesity defined by WC (ObWC) was associated with lower mortality compared with non-obesity (no-ObWC, p=0.013), no difference was shown between obesity, defined by BMI (ObBMI), and non-obesity (no-ObBMI) (p=0.201). When dividing into 4 categories based on high/low of WC and BMI, subjects with high WC and high BMI had the lowest mortality (1.6%) compared to other 3 categories (high WC low BMI; 1.7%, low WC high BMI; 2.4%, or low WC and low BMI; 3.1%). Kaplan-Meier analysis for all cause mortality showed a significant difference between ObWC and no-ObWC (Log Rank p=0.010), but comparable in BMI (ObOMI vs no-ObBMI, p=0.295). This discrepancy was also observed in the analysis for cardiac death (Figure). In multivariate analysis, in addition to age and CKD, ObWC was an independent predictor for the low mortality (OR; 0.582, 95% CI; 0.342-0.991, p=0.046). Conclusions: In Japanese patients with known CAD who undergo PCI, central obesity but not BMI is associated with the paradoxical protective effect of obesity.
T cell activation and anti-tumor efficacy of anti-LAG-3 antibodies is independent of LAG-3 – MHCII blocking capacity
Authors: Saso Cemerski, Shuxia Zhao, Melissa Chenard, Jason Laskey, Long Cui, Rinkan Shukla, Brian Haines, Edward Hsieh, Maribel Beaumont, Jeanine Mattson, Wendy Blumenschein, Heather Hirsch, Laurence Fayadat-Dilman, Linda Liang, Rene De Waal Malefyt
Journal: Journal for ImmunoTherapy of Cancer (2015)

Meeting abstracts LAG-3 has been shown to act as an inhibitory molecule involved in the regulation of T cell activation, proliferation and homeostasis. Exhausted T cell populations that evolve in the tumor microenvironment or during chronic viral infections show coordinated expression of LAG-3 and
Validation of existing clinical prediction models for patients with solitary pulmonary nodules (SPN) managed by a lung multi-disciplinary team (MDT)
Authors: Puneet Malhotra, Natasha Lovell, Paul Plant, Shishir Karthik, Andrew Scarsbrook, Matthew Callister
Journal: European Respiratory Journal (2011)

Background:  Management of patients with SPNs depends critically on the pre-test probability of malignancy. There are currently two clinical predictions models for SPNs based on data from North America. However, these models have not been validated in UK patients, in particular those managed by a Lung MDT.   Objective:  To validate two existing clinical prediction models in patients with SPNs managed by the Lung MDT at a large teaching hospital.   Methods:  175 patients with SPNs measuring 8–30 mm managed by the Lung MDT over 3 years (2007-2009) were identified retrospectively through the institutional Lung Cancer database. Data on age, smoking, cancer history, nodule size, location, spiculation, and final diagnosis was collected. Each case9s final diagnosis was compared with the probability of malignancy predicted by two models: the Mayo Clinic model and the Veteran Affairs (VA) one. The accuracy of each model was assessed by calculating areas under the receiver operating characteristic (ROC) curve and the models were calibrated by comparing predicted and observed rates of malignancy.   Results:  The area under the ROC curve for the Mayo model (0.832; 95% CI 0.753-0.911) was higher than that of the VA model (0.739; 95% CI 0.641-0.838). Calibration curves showed that both models slightly underestimated the probability of malignancy for patients across all deciles of predicted probabilities, except for those with highest probability of malignancy, where the VA model slightly overestimated probability.   Conclusions:  The two existing prediction models are sufficiently accurate to guide management of patients with SPNs managed by a Lung MDT.
The Role of C-Reactive Protein Activation of Nuclear Factor Kappa-B in the Pathogenesis of Unstable Angina⁎⁎Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.
Authors: Ishwarlal Jialal, Sridevi Devaraj
Journal: Journal of the American College of Cardiology (2006)
Comparison of TB-LAMP, GeneXpert MTB/RIF and culture for diagnosis of pulmonary tuberculosis in The Gambia
Authors: Adama L. Bojang, Francis S. Mendy, Leopold D. Tientcheu, Jacob Otu, Martin Antonio, Beate Kampmann, Schadrac Agbla, Jayne S. Sutherland
Journal: Journal of Infection (2015)
Pitx2c increases in atrial myocytes from chronic atrial fibrillation patients enhancing<i>I</i><sub>Ks</sub>and decreasing<i>I</i><sub>Ca,L</sub>
Authors: Marta Pérez-Hernández, Marcos Matamoros, Adriana Barana, Irene Amorós, Ricardo Gómez, Mercedes Núñez, Sandra Sacristán, Ángel Pinto, Francisco Fernández-Avilés, Juan Tamargo, Eva Delpón, Ricardo Caballero
Journal: Cardiovascular Research (2015)

Atrial fibrillation (AF) produces rapid changes in the electrical properties of the atria (electrical remodelling) that promote its own recurrence. In chronic AF (CAF) patients, up-regulation of the slow delayed rectifier K+ current (IKs) and down-regulation of the voltage-gated Ca2+ current (ICa,L) are hallmarks of electrical remodelling and critically contribute to the abbreviation of action potential duration and atrial refractory period. Recent evidences suggested that Pitx2c, a bicoid-related homeodomain transcription factor involved in directing cardiac asymmetric morphogenesis, could play a role in atrial remodelling. However, its effects on IKs and ICa,L are unknown. Real-time quantitative polymerase chain reaction analysis showed that Pitx2c mRNA expression was significantly higher in human atrial myocytes from CAF patients than those from sinus rhythm patients. The expression of Pitx2c was positively and negatively correlated with IKs and ICa,L densities, respectively. Expression of Pitx2c in HL-1 cells increased IKs density and reduced ICa,L density. Luciferase assays demonstrated that Pitx2c increased transcriptional activity of KCNQ1 and KCNE1 genes. Conversely, its effects on ICa,L could be mediated by the atrial natriuretic peptide. Our results demonstrated for the first time that CAF increases Pitx2c expression in isolated human atrial myocytes and suggested that this transcription factor could contribute to the CAF-induced IKs increase and ICa,L reduction observed in humans.
ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody–Drug Conjugate Treatment
Authors: Laetitia E. Lamberts, Catharina W. Menke-van der Houven van Oordt, Eva J. ter Weele, Frederike Bensch, Michiel M. Smeenk, Johannes Voortman, Otto S. Hoekstra, Simon P. Williams, Bernard M. Fine, Daniel Maslyar, Johan R. de Jong, Jourik A. Gietema, Carolien P. Schröder, Alphons H.H. Bongaerts, Marjolijn N. Lub-de Hooge, Henk M.W. Verheul, Sandra M. Sanabria Bohorquez, Andor W.J.M. Glaudemans, Elisabeth G.E. de Vries
Journal: Clinical Cancer Research (2015)

Mesothelin (MSLN) is frequently overexpressed in pancreatic and ovarian cancers, making it a potential drug target. We performed an (89)Zr-PET imaging study with MMOT0530A, a MSLN antibody, in conjunction with a phase I study with the antibody-drug conjugate DMOT4039A, containing MMOT0530A bound to MMAE. The aim was to study antibody tumor uptake, whole-body distribution, and relation between uptake, response to treatment, and MSLN expression.Before DMOT4039A treatment, patients received 37 MBq (89)Zr-MMOT0530A followed by PET/CT imaging 2, 4, and 7 days postinjection. Tracer uptake was expressed as standardized uptake value (SUV). MSLN expression was determined with immunohistochemistry (IHC) on archival tumor tissue.Eleven patients were included, 7 with pancreatic and 4 with ovarian cancer. IHC MSLN expression varied from absent to strong. Suitable tracer antibody dose was 10 mg MMOT0530A and optimal imaging time was 4 and 7 days postinjection. Tumor tracer uptake occurred in 37 lesions with mean SUVmax of 13.1 (±7.5) on PET 4 days postinjection, with 11.5 (±7.5) in (N= 17) pancreatic and 14.5 (±8.7) in (N= 20) ovarian cancer lesions. Within patients, a mean 2.4-fold (±1.10) difference in uptake between tumor lesions existed. Uptake in blood, liver, kidneys, spleen, and intestine reflected normal antibody distribution. Tracer tumor uptake was correlated to IHC. Best response to DMOT4039A was partial response in one patient.With (89)Zr-MMOT0530A-PET, pancreatic and ovarian cancer lesions as well as antibody biodistribution could be visualized. This technique can potentially guide individualized antibody-based treatment.
Prospect: A randomized double-blind phase 3 efficacy study of PROSTVAC-VF immunotherapy in men with asymptomatic/minimally symptomatic metastatic castration-resistant prostate cancer.
Authors: James L. Gulley, Jeannie Lorraine Giacchino, James Bradley Breitmeyer, Alexis J. Franzusoff, Dennis Panicali, Jeffrey Schlom, Philip W. Kantoff
Journal: Journal of Clinical Oncology (2015)

TPS5081 Background: PROSTVAC, a targeted active immunotherapy, is being studied in men with asymptomatic to minimally symptomatic mCRPC in PROSPECT, a global double-blind, randomized phase 3 study. PROSTVAC is a prime-boost regimen consisting of subcutaneous administrations of poxvirus-based PROSTVAC-Prime (a modified vaccinia vector) and PROSTVAC–Boost (a modified fowlpox vector) that encode prostate specific antigen (PSA) as the target antigen with three T-cell co-stimulatory molecules (B7.1, ICAM-1, and LFA-3) also known as TRICOM. A statistically significant overall survival (OS) benefit of 8.5 months (P= 0.0061) with a hazard ratio of 0.56 (95% CI, 0.37 to 0.85), and a favorable risk-benefit profile were reported in a randomized, phase 2 study in mCRPC (Kantoff et. al. 2010 J Clin Onc 28:1099-1105). Methods: In PROSPECT, 1200 subjects have been randomized in a double-blind fashion to three arms: PROSTVAC, PROSTVAC plus GM-CSF, or Placebo at a 1:1:1 ratio. The 5 month treatment regimen comprises one PROSTVAC-Prime injection followed by 6 PROSTVAC-Boost injections. Enrolled subjects have asymptomatic/minimally symptomatic mCRPC and are chemotherapy-naïve. Subjects with rapidly progressing disease and visceral metastases are excluded. The primary endpoint is OS and pre-specified interim analyses are integrated in the statistical plan. Secondary efficacy endpoints include the proportion of event-free subjects at 6 months (radiographic progression, pain progression, chemotherapy initiation, or death) compared to placebo. Exploratory endpoints are planned, including immune responses. An immune monitoring program would inform future immunotherapy studies and potential identification of biomarkers. The trial is fully enrolled. ClinicalTrials.gov registry number: NCT01322490. Clinical trial information: NCT01322490.
Ifosfamide and vinorelbine as first-line chemotherapy for metastatic breast cancer.
Authors: B A Leone, C T Vallejo, A O Romero, J E Perez, M A Cuevas, J A Lacava, C L Sabatini, M E Dominguez, R Rodriguez, M R Barbieri, E H Ortiz, M A Salvadori, L A Acuña, J M Acuña, M J Langhi, S Amato, M R Machiavelli
Journal: Journal of Clinical Oncology (1996)

PURPOSE To evaluate the efficacy and toxicity of the combination of ifosfamide (IFX) and vinorelbine (VNB) as first-line chemotherapy in metastatic breast cancer (MBC). PATIENTS AND METHODS Between August 1993 and August 1995, 45 patients with untreated MBC received a regimen that consisted of IFX 2 g/m2 by 1-hour intravenous (i.v.) infusion on days 1 to 3, mesna 400 mg/m2 by i.v. bolus at hours 0 and 4 and 800 mg/m2 orally at hour 8 on days 1 to 3, and VNB 35 mg/m2 by 20-minute i.v. infusion on days 1 and 15. Courses were repeated every 28 days. During the first course only, half-dose VNB (17.5 mg/m2) was administered on days 8 and 22. The median age was 53 years and 30 patients (67%) were postmenopausal. Dominant sites of disease were soft tissue in nine patients, bone in seven, and visceral in 29. RESULTS Objective responses (ORs) were recorded in 25 of 43 assessable patients (58%; 95% confidence interval, 43% to 73%). Complete remissions (CRs) occurred in six patients (14%) and partial remissions (PRs) in 19 (44%). No change (NC) was recorded in 10 patients (23%) and progressive disease (PD) in eight patients (19%). The median time to treatment failure was 12 months and the median survival duration 19 months. Myelosuppression was the limiting toxicity, mainly leukopenia in 32 patients (74%). In contrast, anemia and thrombocytopenia were mild. Other significant toxicities included peripheral neuropathy in nine patients (21%), constipation in 15 (35%), and myalgias in 11 (26%). CONCLUSION IFX/VNB is an active combination against MBC with moderate toxicity and deserves further evaluation.
Effects of exercise and manual therapy on pain associated with hip osteoarthritis: a systematic review and meta-analysis
Authors: Lucy Beumer, Jennie Wong, Stuart J Warden, Joanne L Kemp, Paul Foster, Kay M Crossley
Journal: British Journal of Sports Medicine (2015)

Aim To explore the effects of exercise (water-based or land-based) and/or manual therapies on pain in adults with clinically and/or radiographically diagnosed hip osteoarthritis (OA). Methods A systematic review and meta-analysis was performed, with patient reported pain assessed using a visual analogue scale (VAS) or the Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain subscale. Data were grouped by follow-up time (0–3 months=short term; 4–12 months=medium term and; &gt;12 months=long term), and standardised mean differences (SMD) with 95% CIs were used to establish intervention effect sizes. Study quality was assessed using modified PEDro scores. Results 19 trials were included. Four studies showed short-term benefits favouring water-based exercise over minimal control using the WOMAC pain subscale (SMD −0.53, 95% CI −0.96 to −0.10). Six studies supported a short-term benefit of land-based exercise compared to minimal control on VAS assessed pain (SMD −0.49, 95% CI −0.70 to −0.29). There were no medium (SMD −0.23, 95% CI −0.48 to 0.03) or long (SMD −0.22, 95% CI −0.51 to 0.06) term benefits of exercise therapy, or benefit of combining exercise therapy with manual therapy (SMD −0.38, 95% CI −0.88 to 0.13) when compared to minimal control. Conclusions Best available evidence indicates that exercise therapy (whether land-based or water-based) is more effective than minimal control in managing pain associated with hip OA in the short term. Larger high-quality RCTs are needed to establish the effectiveness of exercise and manual therapies in the medium and long term.